We discuss how oncogenic alterations, most notably the <sup>V600E</sup>BRAF mutation, act as central drivers of tumor initiation and aggressiveness by sustaining MAPK/ERK signaling, promoting dedifferentiation, metabolic reprogramming, immune evasion, and resistance to targeted therapies. Here, BRAF is linked to neoplasm.